FTSE 100 Bounces Back Amid Energy Stock Gains and Fed Interest Rate Anticipation

London's FTSE 100 index rebounded on Wednesday, driven by rising energy stocks and encouraging corporate updates. The market eagerly awaits the U.S. Federal Reserve's interest rate decision, which could signal a future rate cut. Both FTSE 100 and FTSE 250 are poised for monthly gains, with notable performances from top companies like BP, Shell, and HSBC.

London's FTSE 100 recovered on Wednesday, bolstered by gains in energy stocks and positive corporate updates, as investors eagerly awaited the U.S. Federal Reserve's impending interest rate decision.

The blue-chip FTSE 100 index gained 0.9% after experiencing its worst day of the week on Tuesday. Meanwhile, the mid-cap FTSE 250 index rose by 0.4% by 0707 GMT.

Both indexes are on track to post monthly gains, with the FTSE 250 potentially seeing its best performance this year. Investors' attention is now on the Fed's upcoming monetary policy decision, which could influence global rate cut forecasts.

Although the Fed is broadly expected to hold rates steady, markets are looking for signals of a possible rate cut in September, especially given recent data suggesting cooling inflation. Energy shares in London led broader market gains, rising 1.8% as the index rebounded from Tuesday's losses.

Leading players like BP and Shell each gained more than 1.4%, as geopolitical tensions in the Middle East boosted oil prices by over $1 per barrel. Industrial metal miners also rose by 1.3%, driven by rising base metal prices.

HSBC climbed 2.3% following its announcement to buy back $3 billion in shares and report of stable first-half profits that surpassed estimates, boosting banks by 1.5% to their highest levels since May 2018.

The Bank of England's decision, due on Thursday, is also in focus with a more-than-58% chance of a cut speculated. This potential move would be its first cut since 2020. Additionally, a crucial U.S. jobs report and further quarterly earnings from major U.S. tech companies are on the radar.

Despite forecasting higher annual earnings and sales, GSK slipped 1% after reporting better-than-expected second-quarter results.